Market research
3G0.F Altimmune, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 540M
- P/E ratio
- Not available
- Analyst target
- 30.86
- Dividend yield
- Not available
- Beta
- 0.18
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US02155H2004
- Market cap
- 540M
- P/E ratio
- Not available
- Analyst target
- 30.86
- Dividend yield
- Not available
- Beta
- 0.18
About
About Altimmune, Inc
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 3G0.F discussion.
5 years, 5 months ago
Altimmune, Inc is currently in a long term downtrend where the price is trading 37.1% below its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.0.
Altimmune, Inc's total revenue rose by 301.7% to $2M since the same quarter in the previous year.
Its net income has dropped by 159.3% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 574.4% to $-14M since the same quarter in the previous year.
Based on the above factors, Altimmune, Inc gets an overall score of 2/5.